Chemomab Therapeutics vs Rein Therapeutics
CMMB and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMMB and RNTX compare
Rein Therapeutics scores higher on the StockData Score (6 against 5 for Chemomab Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMMB | RNTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $34.5M |
| Share price | $1.62 | $0.400 |
| Change, 1 year | −36.5% | −70.4% |
| Change, 5 years | −95.4% | −97.0% |
| Beta (5Y) | 2.08 | 2.18 |
| Employees | 10 | 10 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.6× |
| Growth | ||
| EPS growth (TTM) | −53.8% | – |
| EPS growth, 5Y average | −16.4% | – |
| Profitability | ||
| Return on equity | −97.9% | −96.4% (better) |
| Return on invested capital | −8103% | −145% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.41 (better) | 4.27 |
| Altman Z-score | – | −8.75 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −159% |
| Shareholder yield | – | −159% |
| Ownership | ||
| Held by institutions | 0.07% | 47.3% |
| Held by insiders | 27.4% | 9.6% |
| Insider net buying, 12 months | $13.7K | $74.7K (better) |
| Short interest, % of float | – | 0.91% |
Go deeper
- CMMB stock overview
- CMMB income statement
- CMMB valuation and score
- RNTX stock overview
- RNTX income statement
- RNTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.